OS
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Jia Zhong, Kailun Fei, Lin Wu, Baolan Li, Zhijie Wang, Ying Cheng, Xiaoling Li, Xicheng Wang, Liang Han, Xiaohong Wu, Yun Fan, Yan Yu, Dongqing Lv, Jianhua Shi, Jianjin Huang, Shaozhang Zhou, Baohui Han, Guogui Sun, Qisen Guo, Youxin Ji, Xiaoli Zhu, Sheng Hu, Wei Zhang, Qiming Wang, Yuming Jia, Ziping Wang, Yong Song, Jingxun Wu, Meiqi Shi, Xingya Li, Zhigang Han, Yunpeng Liu, Zhuang Yu, An-Wen Liu, Xiuwen Wang, Caicun Zhou, Diansheng Zhong, Liyun Miao, Zhihong Zhang, Hui Zhao, Jun Yang, Dong Wang, Yingyi Wang, Qiang Li, Xiaodong Zhang, Mei Ji, Zhenzhou Yang, Jiuwei Cui, Beili Gao, Buhai Wang, Hu Liu, Lei Nie, Mei He, Shi Jin, Wei Gu, Yongqian Shu, Tong Zhou, Jian Feng, Xinmei Yang, Cheng Huang, Bo Zhu, Yu Yao, Sheng Yao, Jianjun Yu, Shang Li Cai, Yiran Cai, Jiachen Xu, Wei Zhuang, Xianmin Luo, Jianchun Duan, Jie Wang
Signal Transduct Target Ther 9(1) 369
A randomized double-blind phase 3 trial (CHOICE-01, NCT03856411) demonstrated that combining toripalimab with chemotherapy substantially improves progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients without pretreatment. This study presents the prespecified final analysis of overall survival (OS) and biomarkers utilizing circulating tumor DNA (ctDNA) and tissue-based sequencing. Additionally, the analysis revealed a higher median overall survival (OS, 23.8 months) in the toripalimab group than that in the control group (17.0 months). (HR = 0.69, 95%CI: 0.57-0.93, nominal P = 0.01). This survival benefit was particularly notable in the non-squamous subgroup. As the first phase 3 study to perform both baseline tissue whole-exome sequencing (WES) and peripheral blood ctDNA testing, we investigated efficacy predictive biomarkers based on both tissue and ctDNA, Genomic sequencing of ctDNA showed high concordance with tumor tissue independently confirmed that individuals exhibiting a high tumor mutational burden, as well as mutations in the FA-PI3K-Akt and IL-7 signaling pathways benefited more from the toripalimab treatment. Furthermore, a ctDNA response observed on cycle 3 day 1, was associated with improved clinical outcomes for patients treated with the combination therapy. In conclusion, Toripalimab plus chemotherapy yields significant improvements in OS as a first-line treatment. The study highlights the utility of ctDNA as a proxy for tumor tissue, providing novel prospects for predicting efficacy of immuno-chemotherapy through continuous ctDNA monitoring.
3 个 Figure · 5 个 KM 面板
Fig. 2 OS in the Intention-to-Treat Population. a The Kaplan-Meier estimates of OS comparing the toripalimab plus chemotherapy group with the placebo plus chemotherapy group as first-line treatment for patients with advanced NSCLC. Censored patients are marked with “┃” in the graph. Numbers of patients at risk at indicated time points are shown below the x-axis. Number of events, median OS, 1-, 2- and 3-year OS rates, and stratified hazard ratio for death are shown to the right of Kaplan-Meier curves. b Overall survivals in key subgroups. All hazard ratios were computed using the Cox proportional hazards model. All P values were two-sided with no adjustment of multiplicity. The P values of comparing the Kaplan-Meier curves were computed using the log-rank test stratified by the baseline PD-L1 expression status, histology, and smoking status. The P values of testing the interaction of the subgroup variables with the treatment were computed using the Cox proportional hazards regression model with the treatment group, the subgroup variable and their interaction as the covariates. HR, hazard ratio; NA, not available; NSCLC, non–small-cell lung cancer; PD-L1, programmed death ligand-1; PFS, progression-free survival
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 · Panel B
Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 The concordance of mutational landscape between ctDNA and tissue WES data. a The matched frequency of top mutated genes derived from blood-based ctDNA and tumor WES data, ordered by the prevalence rate in ctDNA. b The mutations of top mutated genes between ctDNA profiling and matched tissue were strongly concordant. c The Kaplan-Meier estimates of PFS stratified by bTMB status in ITT patients. Low ctDNA shedders (<5% tumor fraction) were removed to ensure the specimens had subclone mutations adequately captured by the sequencing assay. ctDNA, circulating tumor DNA; WES, whole exome sequencing; TMB, tumor mutational burden; bTMB, blood tumor mutational burden; PFS, progression-free survival; ITT, intention-to-trea;JS001: toripalimab
Fig. 3 · Panel C
Panel C 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 Analyses of ctDNA dynamics at C3D1. a Distribution of tumor load changes in the two arms and association with the best overall response. Tumor load dynamics were categorized into four groups: Negative in both baseline and C3D1 timepoints(BothNeg), Decrease at C3D1(Decrease), Increase at C3D1(Increase), and Reduction to undetectable levels at C3D1(ToNeg). The decrease in the toripalimab arm was more prominent. A higher percentage of patients exhibiting partial response was also observed in the toripalimab group. b Tumor load, as estimated by tumor fraction in blood, decreased at C3D1 for both toripalimab and placebo arms. Response of ctDNA at C3D1 is predictive of PFS ( c ) and OS ( d ) in ITT patients. The ctDNA response was defined as >85% reduction of tumor load from C1D1 or no detection of ctDNA at C3D1. ctDNA, circulating tumor DNA, ITT, intention-to-treat. JS001: toripalimab
Fig. 4 · Panel C
Panel C 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel D
Panel D 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。